27 results
8-K
EX-99.1
RETA
Reata Pharmaceuticals Inc
11 May 20
Reata pharmaceuticals, inc. announces FIRST quarter 2020 financial RESULTS and provides an update on development programs
4:06pm
programs.
Recent Company Highlights
Reata recently announced changes to its clinical programs and operations as a result of the COVID-19 pandemic … -19 pandemic. We have observed no significant data loss during this period.
When the FALCON trial for bardoxolone in ADPKD was paused in March, we
8-K
EX-99.1
RETA
Reata Pharmaceuticals Inc
10 Aug 20
PRE-NDA (NEW DRUG APPLICATION) MEETING GRANTED for Bardoxolone
6:51am
for clinical research, the small number of clinical trial investigators who can conduct the mFARS exam, and the impact of the COVID-19 pandemic … , neuroscience clinical trial now may not be possible because of the COVID-19 pandemic.
At the Type C meeting, to address the FDA’s requirement, FARA, key
8-K
EX-99.1
RETA
Reata Pharmaceuticals Inc
1 Mar 21
Reata pharmaceuticals, inc. announces FOURTH quarter AND FULL YEAR 2020 financial RESULTS and provides an update on CLINICAL DEVELOPMENT programs
6:40am
in FALCON due to the COVID-19 pandemic; we resumed enrollment during the third quarter of 2020. Despite the pandemic, most sites are currently able
8-K
EX-99.1
tlci4ic 5l
11 Jan 21
Regulation FD Disclosure
6:30am
8-K
EX-99.1
k2m3v0uetd
9 Nov 20
Vinny Jindal; Reata Pharmaceuticals Inc.; VP of Strategy
5:30pm
8-K
EX-99.2
jxmr zb72cl2d6r
8 Aug 22
REATA PHARMACEUTICALS, INC. ANNOUNCES Second QUARTER 2022 FINANCIAL
6:45am
8-K
EX-99.3
8pz77wl
9 Nov 20
Reported positive year 2 data from the pivotal CARDINAL study of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome
6:51am
424B5
k23 9lg3tz
1 Dec 20
Prospectus supplement for primary offering
4:17pm